髂股动脉硬化闭塞症金属裸支架置入术后疗效评价

doi:10.12117/jccmi.2020.08.004

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：探讨下肢动脉硬化闭塞症金属裸支架置入术后中长期疗效。方法：回顾性研究我院2012年1月—2017年12月68例髂动脉或股动脉硬化闭塞症患者的资料，其中泛大西洋协会联盟共识Ⅱ（TASC Ⅱ）分期A期6例、B期27例、C期24例、D期11例；Rutherford分级2级5例、3级20例、4级22例、5级21例。结果：患者1年、3年、5年支架通畅率分别为76.1%、59.6%和33.9%。58例患者Rutherford分级下降，术后Rutherford分级为0级10例、1级38例、2级8例、3级7例、4级2例、5级3例。结论：金属裸支架置入术对髂股动脉硬化闭塞症患者有很好的中长期疗效，有效改善患者生存质量。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	梅凯1
	陈磊2
	孙涛2
	闫亮亮2
	郑传胜2

关键词 ：动脉硬化, 闭塞性, 支架, 放射学, 介入性

Abstract：Objective: To evaluate the medium- and long-term effect of bare metal stent implantation in treatment of lower extremity arteriosclerosis obliterans. Methods: Six-eight patients with iliac or femoral arteriosclerosis obliterans from January 2012 to December 2017 in our hospital were reviewed. Six-eight cases of arteriosclerosis obliterans were classified according to the TransAtlantic Inter-Society Consensus Ⅱ(TASC Ⅱ) document, including 6 cases in stage A, 27 cases in stage B, 24 cases in stage C and 11 cases in stage D. The Rutherford classification included 5 cases of grade 2, 20 cases of grade 3, 22 cases of grade 4, and 21 cases of grade 5. Results: The 1-year, 3-year, and 5-year primary patency rates were 76.1%, 59.6%, and 33.9%, respectively. The Rutherford grade was reduced in 58 patients. The postoperative Rutherford grade was: 10 cases of grade 0, 38 cases of grade 1, 8 cases of grade 2, 7 cases of grade 3, 2 cases of grade 4, 3 cases of grade 5. Conclusion: The bare metal stent implantation has a good effect on the patients with iliac or femoral arteriosclerosis obliterans in the medium and long term, and can effectively improve the quality of life of patients.

Key words： Arteriosclerosis obliterans Stents Radiology, interventional

收稿日期: 2020-06-08

PACS:	Ｒ543.5
	Ｒ815

通讯作者: 郑传胜，华中科技大学同济医学院附属协和医院放射科，430022。E-mail：hqzcsxh@sina.com

作者简介: 梅凯（1981-），男，湖北黄冈人，主治医师。E-mail：576288090@qq.com

引用本文:

梅凯1，陈磊2，孙涛2，闫亮亮2，郑传胜2. 髂股动脉硬化闭塞症金属裸支架置入术后疗效评价[J]. 中国临床医学影像杂志, 2020, 31(8): 543-543.
MEI Kai1, CHEN Lei2, SUN Tao2, YAN Liang-liang2, ZHENG Chuan-sheng2. Evaluation of the effect of bare metal stent placement in the treatment of iliofemoral arteriosclerosis obliterans. JOURNAL OF CHINA MEDICAL IMAGING, 2020, 31(8): 543-543.

链接本文:

http://www.jccmi.com.cn/CN/10.12117/jccmi.2020.08.004 或 http://www.jccmi.com.cn/CN/Y2020/V31/I8/543

[1]Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis[J]. Lancet, 2013, 382(9901): 1329-1340. [2]Conte SM, Vale PR. Peripheral Arterial Disease[J]. Heart Lung Circ, 2018, 27(4): 427-432. [3]Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease(TASC Ⅱ)[J]. J Vasc Surg, 2007, 45(Suppl S): S5-67. [4]刘文导，冯柳迁，孟凡喆，等. 下肢动脉硬化闭塞症介入治疗效果及影响术后复发因素分析[J]. 介入放射学杂志，2017，26（6）：514-517. [5]Ratnam L, Raza SA, Horton A, et al. Outcome of aortoiliac, femoropopliteal and infrapopliteal endovascular interventions in lesions categorised by TASC classification[J]. Clin Radiol, 2012, 67(10): 949-954. [6]李艳奎，吴义生，张小明. TASC-D型下肢动脉硬化闭塞症腔内治疗现状[J]. 介入放射学杂志，2015，24（6）：544-547. [7]Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg(BASIL): multicentre, randomised controlled trial[J]. Lancet, 2005, 366(9501): 1925-1934. [8]李京雨，刘涛，路军良，等. 介入治疗复杂下肢动脉硬化闭塞症技术与疗效分析[J]. 中华放射学杂志，2011，45（10）：960-963. [9]Lucatelli P, Cini M, Tommasino G, et al. Use of the Gore Tigris Vascular Stent in Advanced Femoropopliteal Peripheral Arterial Disease[J]. J Vasc Interv Radiol, 2018, 29(5): 614-622. [10]Ding Y, Zhou M, Wang YG, et al. Comparison of Drug-Eluting Stent With Bare-Metal Stent Implantation in Femoropopliteal Artery Disease: A Systematic Review and Meta-Analysis[J]. Ann Vasc Surg, 2018, 50: 96-105. [11]Stavroulakis K, Torsello G, Manal A, et al. Results of primary stent therapy for femoropopliteal peripheral arterial disease at 7 years[J]. J Vasc Surg, 2016, 64(6): 1696-1702. [12]Mohr PJ, Oyama JK, Luu JT, et al. Clinical outcomes of endovascular treatment of TASC-Ⅱ C and D femoropopliteal lesions with the Viabahn endoprosthesis[J]. Cardiovasc Revasc Med, 2015, 16(8): 465-468. [13]Lee SC, Joh JH, Chang JH, et al. Hybrid Treatment of Multilevel Revascularization in Patients With Peripheral Arterial Disease—A Multi-Centre Study in Korea[J]. Vasa, 2018, 47(3): 235-241. [14]Lu L, Mackay DF, Pell JP. Meta-analysis of the association between cigarette smoking and peripheral arterial disease[J]. Heart, 2014, 100(5): 414-423. [15]Leibson CL, Ransom JE, Olson W, et al. Peripheral arterial disease, diabetes, and mortality[J]. Diabetes Care, 2004, 27(12): 2843-2849. [16]Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus[J]. Ann Intern Med, 2004, 141(6): 421-431.